|
|
 |
|
Viewing report
|
|
|
|
How to Integrate Personalized Medicine into Business Strategies
Decision Resources, Inc., Sep 2008, Pages: 37
A growing awareness is taking hold across the pharmaceutical industry: what was once impossible—tailoring treatment to specifi c groups of patients rather than to the population as a whole—is becoming possible. What is needed to integrate a personalized medicine approach into business strategies? We provide perspectives from pharmaceutical, diagnostic, and managed care executives and create a set of recommendations based on what experts advise when contemplating the operational shift to the delivery of personalized healthcare.
Get the Answers You Need to Shape Your Strategy
- Lilly has said it needs to transform every part of its operations. How is Lilly working to integrate a personalized medicine approach into its business strategies? What is entailed in the company’s culturaland organizational restructuring and its new FIPNet model?
- Roche completed a hostile takeover of Ventana and announced its intention to assume complete control of Genentech. Why are these two strategic maneuvers so important to Roche and why are they important to integrating personalized medicine strategies more tightly into the company’s operations? Does personalized medicine success require that a company consume its diagnostic or targeted therapy partner outright and own it lock, stock, and barrel?
- The pharmaceutical industry has adopted formularies and benefi t plan designs to differentiate drugs. What are the problems covering and reimbursing genetic testing and pharmacodiagnostic tests? What problems continue to plague gene-based testing and value-added reimbursement?
Scope
- Business models and strategies: FIPNet, outsourcing, precompetitive collaboration, personalized medicine, fully integrated pharmaceutical company (FIPCO), virtual companies, nichebusters, operational efficiencies, cost-cutting, mega-mergers, consolidation, control versus ownership,
decentralized management, hub and spoke business.
- Diagnostic issues: Trends in genetic tests and genetic testing, improving the predictability of biomarker discovery, standardizing biomarkers, analytic validity, clinical utility, clinical validity, integrating diagnostic development into clinical development, fluorescence imaging, molecular diagnostics, gene profiling, biological signatures, tissue-based diagnostics.
- Pharmaceutical issues: Tailored therapies, disease biology areas, deal making, innovation, information flow and unfettered access to research, nichebusters, patient phenotypes, health outcomes, value-for-money.
- RxDx partnership issues: Adequate control of intellectual property, structuring the relationship, structuring the deal, what to look for in a diagnostic partner.
- Managed care issues: Value-added reimbursement, revamping CPT codes, cost-containment, evidentiary-based review, health policy technology assessments, physician and patient education strategies, direct-to-consumer marketing.
- Two Spectrum, Personalized Medicine Scorecards: Executive insights from transcripts of Lilly and Roche company presentations to investors.
- Expert commentaries: Executives from Iris BioTechnologies, Roche, and VisEn Medical share their insights on genetic tests, targeted therapies, personalized medicine development, transitioning from research to the clinic, and healthcare coverage and reimbursement.
- Interviews: Senior directors from two health benefi t insurers share their insights on genetic and pharmacogenomic tests, evidence-based review, coding, and reimbursement issues.
Customers who bought this item also bought
Dealmaking and Business Strategies in the Age of Personalized Medicine
Personalized Medicine: The Impact of Pharmacogenomics on Pharmaceutical R&D and Sales
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
Biomarkers: The Future of Next-Generation Drug R&D
Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Pharmacogenomics for Clinical Use and in Drug Development
Emerging Medical Technologies Report
|
|
|
|
